Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CureVac secures new hire for preclinical development
March 2019
SHARING OPTIONS:

TÜBINGEN, Germany & BOSTON—Dr. Stefan Mueller has joined CureVac AG as its new vice president preclinical, the company announced last month. In this position, Mueller will manage CureVac’s preclinical programs from discovery to IND filing, and will be responsible for advancing the company’s pipeline. Most recently, Mueller served as global program leader for Rituximab biosimilar at Sandoz Biopharmaceuticals, and he has also held positions at Merck Serono, Merck and Knoll GmbH in the fields of toxicology, drug discovery and early drug development.
 
“It is an honor to join CureVac during this exciting time in the field of mRNA science,” Mueller commented in a statement. “CureVac is leading the way with its mRNA technology, and I look forward to utilizing it to better define preclinical product candidates that advance our mission to revolutionize human health through the unlimited possibilities of mRNA.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.